News and Media
OICR welcomes four new Board members
Four distinguished professionals with a broad range of experience have joined OICR’s Board of Directors.

Four distinguished professionals with a broad range of experience have joined OICR’s Board of Directors.

Mr. Rodney Cheung, Ms. Peggy Gilmour, Dr. Anne-Marie Mes-Masson and Ms. Andrea Redway were elected to the Board on Sept. 22 and will serve three-year terms.

  • Rodney Cheung, P. Eng, EMBA is the Global Chief Information Officer at facilities management company BGS. He has more than 30 years of experience leading start-ups and multinational companies through significant change, and will join the Board’s Audit, Finance and Risk (AFR) Committee as Co-Chair.
  • Peggy Gilmour, CPA, CA, CRMA, ICD.D has held executive roles with major Canadian banks and insurance providers, specializing in audit, risk management, regulatory compliance, finance and operations and technology. She is the former Chief Auditor of Metrolinx and has served on several boards of directors. Gilmour is to assume the role of AFR Co-Chair.
  • Anne-Marie Mes-Masson, PhD is a Professor in the University of Montreal’s Faculty of Medicine and Deputy Scientific Director, Basic and Translational Research at the Centre de recherche du Centre hospitalier de l’Université de Montréal. Her research is largely focused on delivering personalized medicine, including the development of new therapeutic agents for ovarian and prostate cancers. Mes-Masson co-chaired OICR’s 2020 external review.
  • Andrea Redway, LLB is a lawyer who has practiced law in Canada and China and worked on international justice reform in countries in Asia, Africa and Latin America. In 2015, Andrea was diagnosed with Stage 4 lung cancer and has a first-hand understanding of the importance of cancer research. She will serve as Patient Representative on OICR’s Board.

OICR President and Scientific Director Dr. Laszlo Radvanyi thanked the new Board members for taking on these significant leadership positions.

“On behalf of everyone at OICR, I want to welcome Rodney, Peggy, Anne-Marie and Andrea to our Board. We are very fortunate to have them,” Radvanyi said. “Their diverse expertise will help solidify OICR’s position as a world leader in translational cancer research and help us deliver solutions to the biggest challenges in cancer now and into the future.”

OICR’s volunteer Board of Directors is responsible for the overall governance of the Institute. It is comprised of 16 members from various academic and professional disciplines and is chaired by Ms. Susan Fitzpatrick.